| Type | Title | Date Released | |
|---|---|---|---|
4 | Capper Joseph H (Reporting) | ||
4 | Plovanic William J. (Reporting) | ||
8-K | TELA Bio, Inc. Holds Special Meeting of Stockholders and Regains Nasdaq Compliance | ||
8-K | TELA Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement | ||
8-K | TELA Bio Announces U.S. FDA 510(k) Clearance for Liora Monofilament Scaffold | ||
8-K | TELA Bio Enters into Limited Consent to Credit Agreement | ||
4 | Capper Joseph H (Reporting) | ||
8-K | TELA Bio Faces Nasdaq Delisting Notice and Plans Reverse Stock Split to Regain Compliance | ||
4 | Capper Joseph H (Reporting) | ||
DEF 14A | Form DEF 14A | ||
PRE 14A | Form PRE 14A | ||
8-K | TELA Bio Announces COO/CFO Transition and Strategic Cost Reduction Initiative |